Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 9,143 matching trials from the live ClinicalTrials.gov search.

Filters: Rochester, Minnesota Clear all

Conditions: Prostate Cancer
Interventions: allogeneic tumor cell vaccine, therapeutic autologous dendritic cells; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Congenital Adrenal Hyperplasia
Interventions: Tildacerfont/Placebo; Drug
Lead sponsor: Spruce Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 28
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more

Conditions: Recurrent Pericarditis
Interventions: VTX2735; Drug
Lead sponsor: Zomagen Biosciences Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 15
States / cities: La Jolla, California • Orange, California • Saint Augustine, Florida + 10 more

Conditions: Ulcerative Colitis
Interventions: MMX mesalamine/ mesalazine; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 34
States / cities: Birmingham, Alabama • Anaheim, California • Garden Grove, California + 30 more

Conditions: Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Castration Resistant Prostatic Cancer
Interventions: JANX007, Darolutamide; Biological · Drug
Lead sponsor: Janux Therapeutics; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more

Conditions: Abdominal Aortic Aneurysms, Aorto-iliac Aneurysms, Juxtarenal Aneurysms
Interventions: Zenith(R) Fenestrated AAA Endovascular Graft; Device
Lead sponsor: Cook Group Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2015
U.S. locations: 14
States / cities: San Francisco, California • Gainesville, Florida • Indianapolis, Indiana + 11 more

Conditions: Upper Body Obesity
Interventions: Exercise; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Macular Degeneration, Age-Related, Geographic Atrophy
Interventions: Galegenimab, Sham Control; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 72
States / cities: Phoenix, Arizona • Tucson, Arizona • Bakersfield, California + 65 more

Conditions: Invasive Aspergillosis
Interventions: Olorofim, AmBisome®; Drug
Lead sponsor: F2G Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 24
States / cities: Birmingham, Alabama • Duarte, California • Sacramento, California + 21 more

Conditions: Primary Hyperoxaluria Type 1 (PH1)
Interventions: Placebo, Lumasiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 6 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 5
States / cities: San Diego, California • Jacksonville, Florida • Rochester, Minnesota + 2 more

Conditions: Myelofibrosis, Polycythemia Vera, Thrombocytosis
Interventions: Ruxolitinib; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 2
States / cities: Rochester, Minnesota • Houston, Texas

Conditions: Obesity, Lifestyle, Healthy, Community Based Programs, Primary Care Referrals
Interventions: Referral to weight loss program; Behavioral
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Tumors
Interventions: MR-guided cryoablation; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 30 Years to 100 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: ADHD, Smoking
Interventions: Osmotic-Release Methylphenidate, Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years to 55 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 6
States / cities: Cambridge, Massachusetts • Rochester, Minnesota • New York, New York + 2 more

Conditions: Metastatic Breast Cancer
Interventions: IMC-A12 (cixutumumab), tamoxifen, Anastrozole, Letrozole, Exemestane, Fulvestrant; Biological · Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 9
States / cities: Scottsdale, Arizona • Chicago, Illinois • Westwood, Kansas + 6 more

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: tipifarnib, etoposide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 70 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 5
States / cities: Atlanta, Georgia • Baltimore, Maryland • Ann Arbor, Michigan + 2 more

Conditions: Breast Cancer
Interventions: Tamoxifen, Anastrozole, Fulvestrant; Drug
Lead sponsor: Priscilla McAuliffe; Other
Eligibility: Female only
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 12
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 8 more

Conditions: Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Exercise Counseling, Exercise Intervention, Internet-Based Intervention, Interview, Medical Device Usage and Evaluation, Questionnaire Administration; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Cystic Fibrosis
Interventions: interferon gamma-1b; Drug
Lead sponsor: InterMune; Industry
Eligibility: 12 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2002
U.S. locations: 17
States / cities: Birmingham, Alabama • Phoenix, Arizona • Palo Alto, California + 14 more

Conditions: COPD
Interventions: Formoterol Fumarate; Drug
Lead sponsor: Dey; Industry
Eligibility: 40 Years and older
Enrollment: 690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2006
U.S. locations: 68
States / cities: Bessemer, Alabama • Birmingham, Alabama • Phoenix, Arizona + 55 more

Conditions: Head and Neck Cancer
Interventions: cetuximab, cisplatin, TdT-mediated dUTP nick end labeling assay, 3'-deoxy-3'-[18F]fluorothymidine, immunohistochemistry staining method, laboratory biomarker analysis, fludeoxyglucose F 18, radiation therapy; Biological · Drug · Genetic + 2 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Myelodysplastic Syndrome
Interventions: decitabine; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 6
States / cities: Scottsdale, Arizona • Denver, Colorado • Rochester, Minnesota + 3 more

Conditions: Suspected Heparin-Induced Thrombocytopenia
Interventions: Desirudin or Argatroban®; Drug
Lead sponsor: Canyon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 24
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Orlando, Florida + 20 more

Conditions: Carotid Artery Plaque
Interventions: Contrast-enhanced ultrasound, Shear Wave Elastography, Ultrasound Examination; Combination Product · Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer

A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis

Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

Zenith(R) Fenestrated Abdominal Aortic Aneurysm (AAA) Endovascular Graft Clinical Study

Exercise-stimulated Muscle Glucose Uptake in Upper Body Obesity

A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Olorofim Aspergillus Infection Study

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Primary Care Referrals to Community-based Lifestyle Programs for Management of Obesity

MR-Guided Cryoablation of Prostate Bed Recurrences

Smoking Cessation for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia

Endocrine Response in Women With Invasive Lobular Breast Cancer

Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer Related Fatigue

Interferon Gamma-1b by Inhalation for the Treatment of Patients With Cystic Fibrosis

Study in Patients With COPD

3'-Deoxy-3'-[18F] Fluorothymidine and Fludeoxyglucose F 18 PET Scans in Evaluating Response to Cetuximab, Cisplatin, and Radiation Therapy in Patients With Advanced Cancer of the Oropharynx, Larynx, or Hypopharynx

Escalation Study to Determine Bioavailability of a Single Oral Dose of Decitabine in Patients With Myelodysplastic Syndrome (MDS)

A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome

New Technologies to Determine Carotid Plaque Vulnerability in Patients With Significant Carotid Plaques